The cutting-edge medtech stocks worth owning
Much was made of the likely rise of the medtech industry during the pandemic, which was understandable given the circumstances. Covid-19 precipitated a marked increase in the number of related deals, and their representative value. But clinical and cost-related imperatives have not altered since then, even if they’ve become less immediate. The lockdowns not only